Literature DB >> 2570117

The anterior pituitary content of neuromedin U-like immunoreactivity is altered by thyrotrophin-releasing hormone and thyroid hormone status in the rat.

J Domin1, J H Steel, N Adolphus, J M Burrin, U Leonhardt, J M Polak, S R Bloom.   

Abstract

In this study we have examined the effects of TRH, thyroid hormones and dopamine on the rat anterior pituitary content of neuromedin U-like immunoreactivity. Oral administration of TRH (20 mg/100 g per day) to euthyroid animals evoked a fivefold increase in peptide content after 12 days of treatment. This effect was found to be dependent upon circulating levels of thyroid hormone, since administration of TRH to thyroidectomized animals failed to show a similar effect without simultaneous treatment with tri-iodothyronine. The possibility that the TRH-induced increase in anterior lobe neuromedin U content reflected alterations in prolactin secretion or synthetic rate was also examined. Treatment of euthyroid animals with a dopamine agonist and antagonist was, however, without effect. These results demonstrate a unique relationship between TRH and thyroid hormone levels in increasing the anterior lobe content of neuromedin U immunoreactivity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2570117     DOI: 10.1677/joe.0.1220471

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  3 in total

Review 1.  Paracrinicity: the story of 30 years of cellular pituitary crosstalk.

Authors:  C Denef
Journal:  J Neuroendocrinol       Date:  2008-01       Impact factor: 3.627

2.  Modulation of galanin and neuromedin U-like immunoreactivity in rat corticotropes after alteration of endocrine status.

Authors:  V Cimini; S Van Noorden; C M Timson; J M Polak
Journal:  Cell Tissue Res       Date:  1993-04       Impact factor: 5.249

3.  Neuromedins U and S involvement in the regulation of the hypothalamo-pituitary-adrenal axis.

Authors:  Ludwik K Malendowicz; Agnieszka Ziolkowska; Marcin Rucinski
Journal:  Front Endocrinol (Lausanne)       Date:  2012-12-05       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.